WebAug 15, 2024 · Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects with non-IPF progressive fibrosing interstitial lung disease (PF-ILD). However, … WebMar 9, 2024 · The randomized placebo-controlled INBUILD trial of nintedanib was conducted in subjects with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF). …
Efficacy & Trials OFEV® (nintedanib) Global OFEV
WebJan 2, 2024 · INBUILD was a randomized, placebo-controlled, double-blind, phase III trial that investigated the efficacy and safety of nintedanib (150 mg twice daily) in patients with PF-ILD other than IPF. The trial randomized 663 patients with PF-ILD other than IPF that affected 10% of lung volume (as observed in the HRCT scan), a predicted FVC ≥45%, and ... Web开馆时间:周一至周日7:00-22:30 周五 7:00-12:00; 我的图书馆 increase credit score by 50 points
Effects of nintedanib in patients with progressive fibrosing ILDs …
WebApr 3, 2024 · Importance: Studies have suggested that greater primary care physician (PCP) availability is associated with better population health and that a diverse health workforce can improve care experience measures. However, it is unclear whether greater Black representation within the PCP workforce is associated with improved health outcomes … WebMar 22, 2024 · The aim of this feasibility study was to investigate the possibility of producing industrial-scale relevant, robust, high drug-loaded (90.9%, w/w) 100 mg dose immediate-release tablets of isoniazid and simultaneously meet the biowaiver requirements. With an understanding of the real-life constrictions on formulation scientists during … WebApr 7, 2024 · In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity compared with placebo, with side-effects that were manageable for most patients. We used data from the INBUILD trial to characterize further the safety and tolerability of nintedanib. Methods increase darkness of type